A simple and sensitive method for the determination of a new angiotensin-AT1 antagonist i.e. CR 3210, 4-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl] -3-(2H-tetrazol-5-yl)quinoline, is described. The assay was utilised to describe the pharmacokinetic profile of the title compound after intravenous and intraperitoneal administration to Sprague Dawley rats. CR 3210 and the internal standard CR 1505 (loxiglumide, 4-[(3,4-dichlorobenzoyl)amino-5-[(3-methoxypropyl)pentylamino]-5-oxopentanoic acid) were isolated from rat plasma by solid-phase extraction. The sorbent extraction material along with the pH in the conditioning solution and the washing volume were considered pivotal parameters for the optimisation of the procedure. The separations were performed by reversed-phase high-performance liquid chromatography with ultraviolet detection. The samples were injected onto the analytical column (Tracer Extrasil ODS1) and detected at 238 nm, giving a retention time of 6.19 min for CR 3210 and 4.39 min for the internal standard, respectively. The selectivity of the method showed to be satisfactory. The mean recovery of CR 3210 from spiked rat plasma was 80.3 at 1 μg/ml and 79.9 at 2 μg/ml. The lower limit of detection (LOD) was taken as 0.014 μg/ml in plasma samples. The lower limit of quantification (LOQ) was taken as 0.02 μg/ml, the lowest calibration standard using 500 μg rat plasma. The procedures were validated according to international standards with a good reproducibility and linear response from 0.02 to 2 μg/ml. The sensitivity of the method allowed for its application to pharmacokinetic studies. The maximal concentration was detected 5′ after the IV administration, whereas no significant absorption was evident after IP administration of CR 3210 to Sprague-Dawley rats. Our study suggests the absence of extensive bio-transformation of the drug in vivo, supported by the evidence that no metabolites were detected in plasma samples. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.

Rizzo, M., Anzini, M., Cappelli, A., Vomero, S., Ventrice, D., De sarro, G., et al. (2003). Determination of a novel angiotensin-AT1 Antagonist CR3210, in biological samples by HPLC. IL FARMACO, 58(9), 837-844 [10.1016/S0014-827X(03)00141-1].

Determination of a novel angiotensin-AT1 Antagonist CR3210, in biological samples by HPLC

Anzini, Maurizio;Cappelli, Andrea;Vomero, Salvatore;
2003-01-01

Abstract

A simple and sensitive method for the determination of a new angiotensin-AT1 antagonist i.e. CR 3210, 4-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl] -3-(2H-tetrazol-5-yl)quinoline, is described. The assay was utilised to describe the pharmacokinetic profile of the title compound after intravenous and intraperitoneal administration to Sprague Dawley rats. CR 3210 and the internal standard CR 1505 (loxiglumide, 4-[(3,4-dichlorobenzoyl)amino-5-[(3-methoxypropyl)pentylamino]-5-oxopentanoic acid) were isolated from rat plasma by solid-phase extraction. The sorbent extraction material along with the pH in the conditioning solution and the washing volume were considered pivotal parameters for the optimisation of the procedure. The separations were performed by reversed-phase high-performance liquid chromatography with ultraviolet detection. The samples were injected onto the analytical column (Tracer Extrasil ODS1) and detected at 238 nm, giving a retention time of 6.19 min for CR 3210 and 4.39 min for the internal standard, respectively. The selectivity of the method showed to be satisfactory. The mean recovery of CR 3210 from spiked rat plasma was 80.3 at 1 μg/ml and 79.9 at 2 μg/ml. The lower limit of detection (LOD) was taken as 0.014 μg/ml in plasma samples. The lower limit of quantification (LOQ) was taken as 0.02 μg/ml, the lowest calibration standard using 500 μg rat plasma. The procedures were validated according to international standards with a good reproducibility and linear response from 0.02 to 2 μg/ml. The sensitivity of the method allowed for its application to pharmacokinetic studies. The maximal concentration was detected 5′ after the IV administration, whereas no significant absorption was evident after IP administration of CR 3210 to Sprague-Dawley rats. Our study suggests the absence of extensive bio-transformation of the drug in vivo, supported by the evidence that no metabolites were detected in plasma samples. © 2003 Éditions scientifiques et médicales Elsevier SAS. All rights reserved.
2003
Rizzo, M., Anzini, M., Cappelli, A., Vomero, S., Ventrice, D., De sarro, G., et al. (2003). Determination of a novel angiotensin-AT1 Antagonist CR3210, in biological samples by HPLC. IL FARMACO, 58(9), 837-844 [10.1016/S0014-827X(03)00141-1].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/2536
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo